GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Isofol Medical AB (OSTO:ISOFOL) » Definitions » Debt-to-Equity

Isofol Medical AB (OSTO:ISOFOL) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Isofol Medical AB Debt-to-Equity?

Isofol Medical AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Isofol Medical AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Isofol Medical AB's Total Stockholders Equity for the quarter that ended in Mar. 2024 was kr112.95 Mil. Isofol Medical AB's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Isofol Medical AB's Debt-to-Equity or its related term are showing as below:

During the past 9 years, the highest Debt-to-Equity Ratio of Isofol Medical AB was 0.05. The lowest was 0.00. And the median was 0.02.

OSTO:ISOFOL's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Isofol Medical AB Debt-to-Equity Historical Data

The historical data trend for Isofol Medical AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Isofol Medical AB Debt-to-Equity Chart

Isofol Medical AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only 0.04 0.05 0.01 0.03 -

Isofol Medical AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Isofol Medical AB's Debt-to-Equity

For the Biotechnology subindustry, Isofol Medical AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Isofol Medical AB's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Isofol Medical AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Isofol Medical AB's Debt-to-Equity falls into.



Isofol Medical AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Isofol Medical AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Isofol Medical AB's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Isofol Medical AB  (OSTO:ISOFOL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Isofol Medical AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Isofol Medical AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Isofol Medical AB (OSTO:ISOFOL) Business Description

Traded in Other Exchanges
Address
Arvid Wallgrens Backe 20, Biotech Center, Gothenburg, SWE, SE-413 46
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.

Isofol Medical AB (OSTO:ISOFOL) Headlines

No Headlines